Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 30;12(11):2353-2358.
doi: 10.21037/tlcr-23-466. Epub 2023 Nov 17.

Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer

Maxime Borgeaud  1 , Alex Friedlaender  1   2 , Alfredo Addeo  1
Affiliations
Editorial

Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer

Maxime Borgeaud et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Neoadjuvant immune checkpoint inhibitor; non-small-cell lung cancer (NSCLC); perioperative immune checkpoint inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-466/coif). A.F. received payments from Amgen, AstraZeneca, Roche, Astellas, Takeda, Bristol-Myers Squibb, Merck Sharpe Dohme, Pfizer, Merck, Novartis and Janssen, outside the scope of this manuscript. A.A. reports advisory board fees from Amgen, AstraZeneca, Roche, Astellas, Takeda, Merck Sharpe Dohme, Pfizer, Bristol-Myers Squibb, Merck and Novartis; and speaker’s bureau fees from Eli-Lilly, AstraZeneca, Amgen and Novartis. The other author has no conflicts of interest to declare.

Comment on

  • Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.

References

    1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. 10.1056/NEJMoa031644 - DOI - PubMed
    1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. 10.1056/NEJMoa043623 - DOI - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Saw SPL, Ong BH, Chua KLM, et al. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol 2021;22:e501-16. 10.1016/S1470-2045(21)00383-1 - DOI - PubMed
    1. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010;28:3138-45. 10.1200/JCO.2009.27.6204 - DOI - PubMed